Skip to Main Content (Press Enter)

Logo CNR
  • ×
  • Home
  • People
  • Outputs
  • Organizations
  • Expertise & Skills

UNI-FIND
Logo CNR

|

UNI-FIND

cnr.it
  • ×
  • Home
  • People
  • Outputs
  • Organizations
  • Expertise & Skills
  1. Outputs

Biological and molecular properties of a new avb3/avb5 integrin antagonist

Academic Article
Publication Date:
2005
abstract:
The aim of the present study was to identify specific alpha(v)beta(3)/alpha(v)beta(5) integrin antagonists active on tumor-induced angiogenesis. To this purpose, in vitro integrin-binding assays were used to screen a library of conformationally constrained bicyclic lactam Arg-Gly-Asp -containing pseuclopeptides. The results identified ST1646 as a high-affinity specific ligand for alpha(v)beta(3) and alpha(v)beta(5) integrins with negligible interacting with alpha(5)beta(1) integrin. In all the assays, ST1646 was equipotent to or more potent than the well -characterized integrin antagonists c(RGDfV) and cyclo(Arg-Gly-Asp-D-Phe-[NMe]Val) (EMD121974). In the choriciallantoic membrane assay, topical administration of ST1646 was able to prevent the angiogenic responses elicited by recombinant fibroblast growth factor-2 or vascular endothelial growth factor. In addition, systemic administration of ST1646 in mice exerted a significant antiangiogenic activity on neovascularization triggered by mammary carcinoma MDA-MB435 cells implanted s.c. in a dorsal air sac via a (Millipore Filter Corporation, Bedford, MA) chamber. Moreover, ST1646 delivery via an osmotic pump inhibited the growth and vascularization of tumor xenografts originating from the injection of alpha(v)beta(3)/alpha(v)beta(5)-expressing human ovarian carcinoma cells in nude mice. In agreement with the biochemical and pharmacologic studies, Monte Carlo/Stochastic Dynamics simulation showed that the bicyclic scaffold in ST1646 forced the compound to assume a preferred conformation superimposable to the X-ray conformation Of alpha(v)beta(3)-bound EMD121974. Accordingly, computer-docking studies indicated that the ST1646-003 integrin complex maintains the ligand-receptor distances and interactions observed in the crystalline EMD121974-alpha(v)beta(3) integrin complex. Taken together, these observations indicate that ST1646 represents a dual alpha(v)beta(3)/alpha(v)beta(5) integrin antagonist with interesting biochemical and biological features to be tested in cancer therapy.
Iris type:
01.01 Articolo in rivista
List of contributors:
Manzoni, LEONARDO PIERPAOLO
Handle:
https://iris.cnr.it/handle/20.500.14243/74631
Published in:
MOLECULAR CANCER THERAPEUTICS
Journal
  • Use of cookies

Powered by VIVO | Designed by Cineca | 26.5.0.0 | Sorgente dati: PREPROD (Ribaltamento disabilitato)